Oppenheimer Reiterates Outperform on Compass Pathways, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Positive 61.8%

Neg 0% Neu 0% Pos 61.8%

Oppenheimer analyst Francois Brisebois reiterates Compass Pathways (NASDAQ:CMPS) with a Outperform and maintains $20 price target.